Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Biophore, Its Subsidiary Zenara Pharma, Receive First Approval for Cannabidiol in India
Details : Cannabinoid oral solution has received approval for the treatment of several neurological disorders. It functions by stimulating two receptors, cannabinoid receptor type 1 and type 2, within the endocannabinoid system, maintaining body's homeostatis.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 15, 2023
Lead Product(s) : Cannabidiol
Therapeutic Area : Neurology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Undisclosed
Recipient : Akums Drugs & Pharmaceuticals Ltd
Deal Size : Undisclosed
Deal Type : Partnership
Details : The partnership aims to synergise capabilities, leverage research and bring innovative products in specific therapeutic areas, within the next five years, both in India and other global markets.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
December 01, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Recipient : Akums Drugs & Pharmaceuticals Ltd
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Nirmatrelvir,Ritonavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Zenara Launches Generic Version Of Pfizer Covid Drug Paxlovid
Details : Paxzen (nirmatrelvir) is an oral protease inhibitor that is active against MPRO, a viral protease that plays an essential role in viral replication by cleaving the 2 viral polyproteins.
Brand Name : Paxzen
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 09, 2022
Lead Product(s) : Nirmatrelvir,Ritonavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Prochlorperazine Maleate
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Recipient : ANI Pharmaceuticals Inc
Deal Size : Not Applicable
Deal Type : Not Applicable
ANI Pharmaceuticals Announces the Launch of Prochlorperazine Maleate Tablets USP
Details : The current annual U.S. market for Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg is approximately $30.0 million, according to IQVIA/IMS Health, a leading healthcare data and analytics provider.
Brand Name : Prochlorperazine Maleate-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 29, 2022
Lead Product(s) : Prochlorperazine Maleate
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Recipient : ANI Pharmaceuticals Inc
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Molnupiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : The Medicines Patent Pool
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Biophore Receives Sub-License From MPP to Manufacture and Market Molnupiravir for Covid Treatment
Details : The licences are applicable for both molnupiravir (API) and finished product in capsules form. It enables the company to launch the product within India as well as export to 104 other countries around the world, Biophore India Pharmaceuticals said in a s...
Brand Name : MK-4482
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 20, 2022
Lead Product(s) : Molnupiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : The Medicines Patent Pool
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Nirmatrelvir,Ritonavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Hyderabad's Biophore To Manufacture Ingredients of Pfizer's Covid Drug
Details : Paxlovid (Nirmatrelvir) is an oral protease inhibitor that is active against MPRO, a viral protease that plays an essential role in viral replication by cleaving the 2 viral polyproteins.
Brand Name : Paxlovid
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 19, 2022
Lead Product(s) : Nirmatrelvir,Ritonavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Aviptadil Acetate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Biophore seeks DCGI Emergency Use Approval of Aviptadil for Covid-19
Details : Aviptadil is a synthetic form of vasoactive intestinal peptide (VIP) that, when administered, results in rapid clinical recovery in patients with severe SARS-COV-2 infection. Biophore has successfully developed aviptadil and is backward integrated with i...
Brand Name : Undisclosed
Molecule Type : Peptide
Upfront Cash : Not Applicable
June 11, 2021
Lead Product(s) : Aviptadil Acetate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Aviptadil Acetate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Biophore Applies For DCGI Approval for Emergency Use of Aviptadil to Treat COVID-19
Details : Biophore has developed Aviptadil and is backward integrated with in-house API. The company has also informed that it will be commencing commercial production immediately after the approval is received.
Brand Name : Undisclosed
Molecule Type : Peptide
Upfront Cash : Not Applicable
June 11, 2021
Lead Product(s) : Aviptadil Acetate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Zenara Pharma, a Biophore Subsidiary, Gets DCGI Nod for Favipiravir Tablets
Details : Favipiravir tablets will be sold under the brand name ‘Favizen’, is being manufactured at Zenara’s US FDA approved facility in Hyderabad.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 05, 2020
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Hyderabad Based Biophore India Gets DCGI Nod To Manufacture COVID Drug Favipiravir
Details : Favipiravir is an antiviral agent that was initially discovered and developed because of its activity against another RNA (ribonucleic acid) virus, the influenza virus.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 14, 2020
Lead Product(s) : Favipiravir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
KEY PRODUCTS
Reset All
